ASM
REVBW icon

ATW SPAC Management’s Revelation Biosciences Warrant REVBW Stock Holding History

ATW SPAC Management’s Portfolio REVBW Stock Details REVBW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-216,945
Closed -$2.18M – 161
2021
Q2 		$2.18M Buy
+216,945
New +$129K 0.56% 61

Other funds holding REVBW

MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.21B AUM 169.99% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
ICM
Ionic Capital Management New York $690M AUM 70.34% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

ATW SPAC Management's REVBW Position: Q3 2021 in Review

ATW SPAC Management sold out of Revelation Biosciences Warrant (REVBW) in Q3 2021, closing a stake of 216,945 shares — an estimated $2.18M sold.

ATW SPAC Management first reported a position in REVBW in Q2 2021 and held it in 1 quarter. The position peaked at $2.18M in Q2 2021. 18 funds tracked by Wall St. Rank hold REVBW as of Q3 2021.

  • ATW SPAC Management reported no remaining Revelation Biosciences Warrant position as of Q3 2021 after selling out during the quarter.
  • ATW SPAC Management sold 216,945 Revelation Biosciences Warrant shares in Q3 2021, an estimated $2.18M.
  • ATW SPAC Management first reported a position in Revelation Biosciences Warrant in Q2 2021 and held it in 1 quarter.
  • ATW SPAC Management's Revelation Biosciences Warrant position peaked at $2.18M in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q3 2021.

Based on ATW SPAC Management's 13F filing for Q3 2021, filed 9 Nov 2021.